NCT01604889 2019-03-26A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaIncyte CorporationPhase 1/2 Terminated136 enrolled